Keyword: Eli Lilly

Eli Lilly reports that Humalog's net prices have slipped by 8% in recent years even as the company raised list prices 52%.

FierceMadness Round 2 results are in, with 16 contenders remaining in the March Madness-style pharma DTC ad tournament.

Lilly plans a $91 million plant expansion in Indianapolis, and a $7 million tax abatement tied to the project has generated some debate.

After AstraZeneca released overall CV outcomes results for Farxiga, the company has dug further into the data and presented two subanalyses on Monday.

Despite pricing pressure from domestic rivals, Keytruda could still generate billions of dollars a year in China, Cantor analysts predict

Lilly CEO David Ricks, in his second year on the job, hauled in a pay package larger than those of a few of his big pharma peers.

Eli Lilly has new data that could help expand Cyramza’s lung cancer footprint, but a tough marketing battle awaits.

Lilly could relieve itself of some public pressure with the authorized Humalog generic, but will Sanofi and Novo follow with Lantus and NovoLog?

AbbVie’s Humira was the No. 1 pharma TV ad spender again in February, swapping places with Pfizer’s anti-inflammatory drug Xeljanz.

Novo's oral semaglutide could shake up the coverage landscape as it touches on both the branded orals and the injectable GLP-1s, one analyst says.